ClinicalTrials.gg
CompletedNCT06131749Updated Sep 16, 2025

Genital Tract Infections, the Vaginal Microbiome and Gestational Age at Birth Among Pregnant Women in South Africa

An observational study in Sexually Transmitted Infections (Not HIV or Hepatitis), Premature Birth and Pregnancy; Infection, sponsored by University of Bern. Completed at 1 site in South Africa. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.

Primary conditionHIV InfectionsRegistry: Sexually Transmitted DiseasesReclassifiedWhy we changed it
Registry
Sexually Transmitted Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
HIV Infections
Why
  1. The study's listed conditions name HIV Infections, a narrower term within Sexually Transmitted Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Bern · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
603
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 305 studies in HIV Infections with a site in South Africa — 15 open to participants now, 36 under way, 15 of them phase 3. HIV Infections · South Africa.

Enrollment
15th of 35
603 · median 513
Started
2021
with 16 others
Observational
35 of 305
1 open now
Registered
289th of 305
by date

Among the 305 studies in HIV Infections with a site in South Africa, this one is the 15th largest by enrollment of the 35 observational ones that give a count, is one of 17 that started in 2021, is one of 35 observational ones, and was the 289th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 305 studies in HIV Infections with a site in South Africa are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 305 studies in HIV Infections with a site in South Africa, or all of them as a file.
02

Study summary

This cohort study plans to investigate associations between the presence of multiple lower genital tract microorganisms in pregnancy and gestational age at birth.

The study enrols pregnant women at one public health care facility in East London, South Africa. At enrolment and 30-34 weeks of pregnancy, participants provide swabs for testing for sexually transmitted infections, vaginal yeasts and genital mycoplasmas; for microscopy and Nugent scoring; and for 16S ribosomal ribonucleic acid gene sequencing and quantification. The primary outcome is gestational age at birth.

Statistical analyses include: regression modelling to explore associations between specific microorganisms (including microbiota) and gestational age at birth; construction of an index of vaginal inflammation, using data about microorganism load and inflammatory potential; classification and regression tree analysis to examine which combinations of microorganisms contribute to earlier gestational age at birth.

Read the detailed description

Background: Preterm birth complications are the most common cause of death in children under 5 years. In South Africa, the prevalence of both genital tract infections and adverse pregnancy outcomes are high. This study takes a holistic approach, investigating both the presence and quantity of multiple lower genital tract microorganisms, including vaginal microbiota, in pregnancy and their associations with gestational age at birth. Specific objectives are to explore: (1) the association between the presence of specific lower genital tract microorganisms and gestational age at birth (primary outcome), as well as secondary adverse pregnancy outcomes; (2) the association between quantified load of vaginal and sexually transmitted microorganisms and gestational age at birth (primary outcome) as well as secondary adverse pregnancy outcomes; and (3) the combinations of microorganisms that are most strongly associated with earlier gestational age at birth.

Methods: This prospective closed cohort study follows women enrolled during pregnancy until after they give birth. This cohort study is part of a larger project, called Philani Ndiphile (meaning 'be healthy and I will be healthy' in isiXhosa).

A trained study field worker checks for eligibility and obtains written informed consent. A study nurse performs an abdominal ultrasound to estimate the gestational age and confirm eligibility.

At the enrolment visit and a follow-up visit at 30-34 weeks, a study nurse collects vaginal specimens for: on-site testing for Chlamydia trachomatis and Neisseria gonorrhoeae (with antibiotic treatment if positive); and offsite testing for: Nugent scoring; detection and quantification of Mycoplasma genitalium, M. hominis, Ureaplasma. parvum, U. Urealyticum, Trichomonas vaginalis, Candida spp. and 16S rRNA amplicon sequencing for vaginal microbiota analyses.

At a post-natal visit, 3-6 days after giving birth, a study nurse collects information about the birth outcome.

Statistical analyses include:

Objective 1. a) univariable and multivariable regression analyses for associations between specific microorganisms and gestational age at birth. b) compositional multivariable analysis methods to analyse individual taxon relative abundances and mixed effects models to assess associations between pregnancy outcome and vaginal microbiota diversity, vaginal microbiota types and absolute abundances of predefined bacterial groups.

Objective 2. Development of a 'vaginal inflammation index', based on quantification of the vaginal microbiota and their inflammatory potential. This vaginal inflammation index will be analysed as a fixed effect in mixed effects models with pregnancy outcomes.

Objective 3. Classification and regression tree analyses to examine the combination of microorganisms that best predicts earlier gestational age at birth.

03

Conditions studied

  • Sexually Transmitted Infections (Not HIV or Hepatitis)
  • Premature Birth
  • Pregnancy; Infection
  • Microbial Colonization
  • Chlamydia Trachomatis Infection
  • Neisseria Gonorrheae Infection
  • Trichomonas Vaginitis
  • Mycoplasma Genitalium Infection
  • Bacterial Vaginosis
  • Vaginal Candida
  • Ureaplasma Urealyticum Infection
  • Genital Mycoplasma Infection
  • HIV Infections

Keywords

  • Sexually transmitted infections
  • Preterm birth
  • Gestational age at birth
  • Vaginal microbiome
  • Genital mycoplasmas
  • Organism load
  • Vaginal yeast
  • Antenatal care
04

In context

HIV Infections Reclassified

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

This study's enrollment of 603 is above the median of 200 across 781 observational studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

University of Bern is the lead sponsor of 209 studies on the registry; 46 are open to participants now.

Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sexually Transmitted Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant women receiving antenatal care at one primary health care facility in Buffalo City Metropolitan Municipality, Eastern Cape Province, South Africa.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Living in Buffalo City Metropolitan Municipality
  • Intend to deliver in the same municipality
  • \<27 weeks of gestation at enrolment, confirmed by ultrasound
  • Provide written

Exclusion criteria

Exclusion Criteria:

  • Participation in any other research study
  • Inability to understand and speak a local language (English, Afrikaans, or isiXhosa).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
603 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Pregnant women

    No intervention. Followed during pregnancy at baseline and 30-34 weeks. Followed after delivery at 3-6 days.

    Other: No intervention

Interventions

  • OtherNo intervention

    No intervention, observational cohort study

07

What researchers measure

Primary outcomes

  1. Gestational age at birth

    Gestational age in days, estimated using data from obstetric ultrasound at enrolment visit

    Time frame: Recorded within 2 weeks of delivery

Secondary outcomes

  1. Preterm birth

    Number of babies liveborn before 37 completed weeks of pregnancy, estimated using data from obstetric ultrasound at enrolment visit

    Time frame: Recorded within 2 weeks of birth

  2. Low birth weight

    Number of babies with birth weight \<2500g

    Time frame: Measured within 72 hours of birth

  3. Miscarriage

    Number of foetuses delivered dead before 28 completed weeks of pregnancy or with birth weight below 1000g. Gestational age estimated using data from obstetric ultrasound at enrolment visit

    Time frame: Collected throughout pregnancy until delivery

  4. Stillbirth

    Number of foetuses delivered dead at or after 28 completed weeks of pregnancy or with birth weight above 1000g at delivery. Gestational age estimated using data from obstetric ultrasound at enrolment visit

    Time frame: Collected throughout pregnancy until delivery

Other outcomes

  1. Prevalence of microorganisms

    Number of women with a specific microorganism / number of women tested

    Time frame: Measured at enrolment visit and at 30-34 week visit

  2. Incidence of microorganisms

    Number of women with new detection of a specific microorganism per 1000 woman years of follow-up

    Time frame: Measured at 30-34 week visit

08

Study locations

1 site
  • Empilweni Gompo Community Health Centre
    East London, Eastern Cape 5209, South Africa
09

References and documents

Publications

  • Gigi RMS, Mdingi MM, Jung H, Claassen-Weitz S, Butikofer L, Klausner JD, Muzny CA, Taylor CM, van de Wijgert JHHM, Peters RPH, Low N. Genital tract infections, the vaginal microbiome and gestational age at birth among pregnant women in South Africa: a cohort study protocol. BMJ Open. 2023 Dec 28;13(12):e081562. doi: 10.1136/bmjopen-2023-081562. PubMed 38154893 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Apr 2024, 37 months.

Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's 37 months is close to that.

Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2023
First posted
Nov 14, 2023
StartActual
Mar 1, 2021
Primary completionActual
Apr 30, 2024
CompletionActual
Jul 31, 2024
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06131749
Lead sponsor
University of Bern
Collaborators
Foundation for Professional Development, Utrecht University, University of Pretoria, University of Cape Town, University of Southern California, University of Alabama at Birmingham, Louisiana State University Health Sciences Center in New Orleans
Responsible party
Sponsor
First posted
Nov 14, 2023
Start date
Mar 1, 2021
Primary completion
Apr 30, 2024
Completion
Jul 31, 2024
Last update
Sep 16, 2025

Study contacts

Nicola Low, MD
principal investigator · University of Bern

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion